| 1 |
34782346 | BET Inhibition Enhances TNF-Mediated Antitumor Immunity. | 2022 Jan |
1 |
| 2 |
34954522 | The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. | 2022 Jan 15 |
4 |
| 3 |
35402244 | Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor. | 2022 |
2 |
| 4 |
33712563 | Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4. | 2021 Mar 12 |
2 |
| 5 |
34249442 | Epigenetic heterogeneity promotes acquired resistance to BET bromodomain inhibition in ovarian cancer. | 2021 |
1 |
| 6 |
34829934 | Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). | 2021 Nov 17 |
2 |
| 7 |
32453591 | Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. | 2020 Jul 9 |
1 |
| 8 |
32575711 | Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis. | 2020 Jun 20 |
4 |
| 9 |
32859084 | Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for Osteosarcoma. | 2020 Aug 26 |
1 |
| 10 |
31288832 | Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. | 2019 Jul 9 |
1 |
| 11 |
31300040 | Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. | 2019 Jul 12 |
1 |
| 12 |
31406246 | The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. | 2019 Oct |
1 |
| 13 |
29180474 | Vitamin C Sensitizes Melanoma to BET Inhibitors. | 2018 Jan 15 |
2 |
| 14 |
29346775 | BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. | 2018 Jan 16 |
1 |
| 15 |
29622725 | SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. | 2018 May 18 |
1 |
| 16 |
30466442 | BRD4 and Cancer: going beyond transcriptional regulation. | 2018 Nov 22 |
2 |
| 17 |
28042144 | Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. | 2017 Sep |
1 |
| 18 |
28249162 | BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. | 2017 Feb 28 |
1 |
| 19 |
28981843 | RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. | 2017 Nov 2 |
1 |
| 20 |
26983878 | Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. | 2016 Jun |
1 |
| 21 |
27650498 | Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. | 2016 Nov 4 |
1 |
| 22 |
25944566 | BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. | 2015 May 6 |
1 |